服用奥拉迪约的副作用

In the pivotal Phase 3 APeX-2 trial, Orladeyo significantly reduced HAE episodes at week 24 of treatment, and this reduction was sustained through week 48. Among HAE patients who completed 48 weeks of treatment (150 mg), the HAE attack rate decreased from an average of 2.9 attacks per month at baseline to an average of 1.0 attacks per month after 48 weeks of treatment. In the long-term open-label APeX-S trial, patients with HAE who completed 48 weeks of treatment (150 mg) experienced an average of 0.8 exacerbations per month.

Orladeyo was safe and well-tolerated in 2 trials. The most common adverse reactions reported by patients taking oral Orladeyo compared with placebo were gastrointestinal reactions. These reactions usually occur early after starting treatment with Orladeyo, become less frequent over time, and usually resolve on their own.

The most common adverse reactions (≥10% higher than placebo) in patients receiving Orladeyo were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease.

For patients with moderate or severe hepatic impairment (Child-Pugh B or C) and those taking long-term treatment with P-glycoprotein (P-gp) or breast cancer resistance protein, a reduced oral dose of 110 mg once daily with food is recommended. BCRP) inhibitors (e.g. cyclosporine).

Currently (Orladeyo) is not listed in our country, so it is not eligible for medical insurance. In other words, if patients want to purchase the drug, they must go abroad to purchase it. Traveling abroad to buy medicines is a long journey and requires a lot of manpower and material resources. Coupled with the huge medical expenses, many patient families are overwhelmed. However, as far as Medical Companion Travel currently knows, Oladiyo is more cost-effective than other versions, and it is directly mailed overseas, which is convenient and fast, and 100% authentic. Since the exchange rate has been in a state of fluctuation for a long time, the price fluctuates with the exchange rate and is not static. For more information about Oradieu, please contact Medical Companion Travel for details.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.